Platelet rich plasma (PRP) enhances the bone and soft-tissue healing by placing the autologous platelets at the site of tissue damage.
The key competitors in the global platelet-rich plasma market are have a strong presence across North America, which has boosted the growth of the platelet-rich plasma market in the region. Consequently, in 2013, North America held over 50% of the market. However, the market players are looking eastward and are investing in emerging markets across Asia Pacific to expand their business.
As a result, Asia Pacific has emerged as the fastest developing market for platelet-rich plasma. The rising awareness about PRP products and devices across the developing economies has played a key role in the development of this regional PRP market. “The development of new PRP devices and, commercialization and promotion of these devices would open new avenues for the market players,” a TMR analyst recommends.
The key competitors in the global PRP market have been registering an increased demand for leukocyte-rich PRP or L-PRP. The L-PRP segment is anticipated to be the fastest growing segment among the other types of platelet-rich plasma in the coming years. Earlier, in 2013, pure platelet-rich plasma or P-PRP accounted for 60% of the overall market.
Risks of Therapy Failure Cast Shadow over Growth of Global Platelet-Rich Plasma Market
The growing prevalence of orthopedic diseases and sports injuries has propelled the demand for platelet-rich plasma for orthopedic surgeries. Rise in cosmetic surgeries, coupled with technological advancements and regulatory approvals for new devices has supported the market’s growth. However, the high cost of PRP products and devices might impede the growth of the market in the coming years. “Threats of therapy failure and disease transfer in case of homologous and allogenic PRP might resist the expansion of the market,” the analyst points out.
Get Free Sample Research Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4021
Orthopedic Surgeries to Drive Demand for Platelet-Rich Plasma
In terms of origin, platelet-rich plasma is categorized into allogenic, autologus, and homologus. The autologus segment held the largest market share in 2013. However, the allogenic segment is anticipated to witness the highest demand during the forecast period. Platelet-rich plasma is widely used across cosmetic surgery, orthopedic surgery, neurosurgery, general surgery, and others. The orthopedic surgery segment dominated the overall market in 2013. “Platelet-rich plasma technologies lead to cost-effective orthopedic surgeries,” TMR states.
The global platelet-rich plasma market is anticipated to expand at a CAGR of 11.9% during the period between 2014 and 2020. The market stood at a valuation of US$0.16 bn in 2013 and is projected to be worth US$0.35 bn by 2020.
As a result, Asia Pacific has emerged as the fastest developing market for platelet-rich plasma. The rising awareness about PRP products and devices across the developing economies has played a key role in the development of this regional PRP market. “The development of new PRP devices and, commercialization and promotion of these devices would open new avenues for the market players,” a TMR analyst recommends.
The key competitors in the global PRP market have been registering an increased demand for leukocyte-rich PRP or L-PRP. The L-PRP segment is anticipated to be the fastest growing segment among the other types of platelet-rich plasma in the coming years. Earlier, in 2013, pure platelet-rich plasma or P-PRP accounted for 60% of the overall market.
Risks of Therapy Failure Cast Shadow over Growth of Global Platelet-Rich Plasma Market
The growing prevalence of orthopedic diseases and sports injuries has propelled the demand for platelet-rich plasma for orthopedic surgeries. Rise in cosmetic surgeries, coupled with technological advancements and regulatory approvals for new devices has supported the market’s growth. However, the high cost of PRP products and devices might impede the growth of the market in the coming years. “Threats of therapy failure and disease transfer in case of homologous and allogenic PRP might resist the expansion of the market,” the analyst points out.
Get Free Sample Research Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4021
Orthopedic Surgeries to Drive Demand for Platelet-Rich Plasma
In terms of origin, platelet-rich plasma is categorized into allogenic, autologus, and homologus. The autologus segment held the largest market share in 2013. However, the allogenic segment is anticipated to witness the highest demand during the forecast period. Platelet-rich plasma is widely used across cosmetic surgery, orthopedic surgery, neurosurgery, general surgery, and others. The orthopedic surgery segment dominated the overall market in 2013. “Platelet-rich plasma technologies lead to cost-effective orthopedic surgeries,” TMR states.
The global platelet-rich plasma market is anticipated to expand at a CAGR of 11.9% during the period between 2014 and 2020. The market stood at a valuation of US$0.16 bn in 2013 and is projected to be worth US$0.35 bn by 2020.
No comments:
Post a Comment